Anupam Rasayan is one of the leading company  engaged in the custom synthesis and manufacturing of specialty chemicals in India. In custom synthesis and manufacturing operations, the processes and technical specifications are developed in-house, and the product is made for a specific customer. The company has two distinct business verticals (i) life science related specialty chemicals comprising products related to agrochemicals, personal care and pharmaceuticals, and (ii) other specialty chemicals, comprising specialty pigment and dyes, and polymer additives.

Anupam Rasayan India Ltd. IPO

Wants To Apply Online



                                                            Issue Details
Objects of the issue ·          To Repayment/prepayment of certain indebtedness including accrued interest

·          To meet general corporate purposes.

Issue Size Total issue Size -Rs. 760Cr.

Fresh Issue – Rs 760  Cr.

Employee Reservation – 220,000 shares

Face value  

Rs.10 Per Equity Share

Issue Price Rs. 553 – Rs. 555
Bid Lot 27 shares
Listing at  


Issue Opens: 12th March, 2021 – 16th  March, 2021
QIB 50% of Net Issue Offer
Retail 35% of Net Issue Offer
NIB 15% of Net Issue Offer


Financial Performance:


Shareholding Pattern:

Shareholding Pattern Pre- Issue Post Issue
Promoters & Promoters Group 75.80% 65.41%
Public 24.20% 34.59%
Source: RHP, EWL Research,


Check Anupam Rasayan India Ltd. IPO Allotment Status

Anupam Rasayan India Ltd. IPO allotment status would be available soon after the IPO closure date. Usually the allotment comes within a week from the closing date which in this IPO yet to be announced.

One can check the allotment on the given below link with PAN number or Application number or DP Client Id. All you need to do is to follow these steps:-

  1. To Anupam Rasayan India Ltd. IPO Allotment Status
  2. Go to Application Status
  3. Select IPO as Anupam Rasayan India Ltd.
  4. Enter your PAN Number or Application Id or DP Client Id.


Anupam Rasayan India Ltd. IPO

Application Form




  • Strong and long-term relationships with diversified customers across geographies with significant entry barriers

  • Core focus on process innovation through consistent research and development, value engineering and complex chemistries

  • Diversified and customized product portfolio with a strong supply chain

Key Highlights:

  • Revenue from operations has grown at a CAGR of 24.29% during FY18-FY20.

  • Net Profit margin of the company declined from 11.5% in 9MFY20 to 8.9% in 9MFY21 due to 52% YoY rise in raw material cost.

  • Top 10 customers represented 84.01% of revenue from operations in the nine months ended December 31, 2020.

  • D/E ratio of the company decreased from 1.38 in FY19 to 1.20 in 9MFY21.

  • 3% Revenue of the company comes from exports.

  • RoE of the company reduced from 10.21% in FY19 to 6.78% in

Risk Factors:

  • Incurred significant indebtedness which it may not comply with repayment.

  • May experience insufficient cash flows to meet required payments on debt and working capital requirements.

  • Experienced negative cash flows from operating activities in Fiscal 2018 and may, in the future, experience negative cash flows.

  • Restrictions on import of raw materials and an increase in shipment cost may adversely impact business


Anupam Rasayan manufacture agro intermediates and agro active ingredients in life sicence chemicals segment for the agrochemicals industry which are used in the manufacture of  insecticides, fungicides and herbicides and has strong and long-term relationships with various multinational corporations, including, Syngenta Asia Pacific Pte. Ltd., Sumitomo Chemical Company Limited and UPL Limited. In life science related specialty chemicals segment, Agro Revenue constitute 67.34% of total revenue of the company. Revenue of the company from Europe, Japan and India accounted for 35.97%, 5.83% and 31.95%, respectively, in Fiscal 2020, and 31.43%, 15.32% and 38.66%, respectively, in the nine months ended December 31, 2020. Indian crop protection chemicals exports have grown at a CAGR of almost 9% to US$ 2.1 billion between 2015 – 2019. By 2024, exports are expected to grow at a CAGR of 10.23 percent to US$ 3.1billion.  At the higher end of the price band of Rs. 555, the stock is offered  at a PE multiple of 89.9x on FY21E annualised Post issue EPS of Rs. 7.12 whereas Industry has highest P/E ratio of 65.7. We would recommend Listing gain to this IPO to risk aversion investors considering  high valution  of the company. However investors with long term perspective can invest to the IPO for longer term.

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth
Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their
investment decision and must exercise their own judgment before making any investment decision.
For analyst certification and other important disclosures, see the Disclosure Appendix, or go to Analysts employed by Elite Wealth
Limited are registered/qualified as research analysts with SEBI in India. (SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Manoj Vijay Shinde, Elite Wealth Limited,
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their
securities. I/We also certify that no part of my compensation was, is or will be, directly or inirectly, related to the specific recommendations or views expressed in this
report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that
the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment
thesis, valuation methodology, and risks to rating and price targets, please visit
Company-Specific Disclosures
Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting, or emailing with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research.
For important disclosures for these companies, please e-mail
Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure
documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available
to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.
Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of
coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth
Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, advisory board member or employee of any company
in the analyst’s area of coverage.
Country Specific Disclosures
India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. RavinderParkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course
Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and
Exchange Board of India. Telephone:011-43035555, Facsimile: 011-22795783 and Website:
EWL Advisory discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research
report, details of associates and such other information as is necessary to take an investment decision, including the following:
1. Reports
a) EWL Advisory or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL Advisory or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of
the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL Advisory or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public
2. Compensation
(a) EWL Advisory or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL Advisory or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL Advisory or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company
in the past twelve months;
(d) EWL Advisory or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage
services from the subject company in the past twelve months;
(e) EWL Advisory or its associates have not received any compensation or other benefits from the subject company or third party in connection with the research
3 In respect of Public Appearances
(a) EWL Advisory or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided
by EWL Advisory
Provided that research analyst or research entity shall not be required to make a disclosure as per sub-clauses (c), (d) and (e) of clause (ii) or sub-clauses (a) and (b) of
clause (iii) to the extent such disclosure would reveal material non-public information regarding specific potential future investment banking or merchant banking or
brokerage services transactions of the subject company.
(4) EWL Advisory or its proprietor has never served as an officer, director or employee of the subject company;
(5) EWL Advisory has never been engaged in market making activity for the subject company;
(6) EWL Advisory shall provide all other disclosures in research report and public appearance as specified by the Board under any other regulations.